Immunotherapy Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Clarithromycin

Clarithromycin extended-release is an efficacious antibacterial option

According to a review from the United States, "Clarithromycin extended-release (ER) is a second-generation macrolide with bactericidal activity against a broad group of pathogens.

K.N. Williams and colleagues, Johns Hopkins School of Medicine, wrote, "It allows for convenient once-daily dosing (2 x 500 mg/day), and has less severe adverse effects than the immediate-release (IR) formulation of the drug, which may result in improved patient compliance.

"Clarithromycin ER has been approved for the treatment of community-acquired pneumonia, acute maxillary sinusitis...

• View Other Issues of Immunotherapy Weekly
  
• View Other NewsRx Publications